{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-23-000040","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.382499+00:00","generated_at":"2026-06-08T19:51:39.790988+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeuroPace Q3 revenue $16.4M (+47% YoY), raises FY2023 guidance to $62.5-$63.5M","bullets":["Revenue $16.4M (+47% YoY); net loss $7.3M vs $11.8M a year ago.","Cash burn reduced to $2.2M in Q3, down from $4M in Q2 and $9.8M in Q1.","Full-year revenue guidance raised to $62.5-$63.5M (prev $59-$61M); gross margin guided 71%-73%.","FDA approved Tablet Remote Monitor; launched nSight platform. NAUTILUS trial enrollment on track for Q1 2024.","First RNS implants in community setting under Project CARE; sufficient cash to fund operations into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-23-000040","json":"https://secwatch.observer/filing/0001528287-23-000040.json","markdown":"https://secwatch.observer/filing/0001528287-23-000040.md","text":"https://secwatch.observer/filing/0001528287-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000040/0001528287-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000040/npce-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:51:39.790988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9997e086473aa1d16df647b1e563a759272375d1","claim":"NeuroPace Inc reported third quarter ended September 30, 2023 results: revenue $16.4 million, net income $(7.3 million). Guidance raised.","evidence_excerpt":"NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance Third quarter 2023 revenue of $16.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000040/0001528287-23-000040-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$16.4 million"},{"label":"Net income","value":"$(7.3 million)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}